Business
Save the Date: Profound Medical to Host Investor Event at AUA 2025
TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#...
About this update from Profound Medical Corp
[{"type":"text","content":"Save the Date: Profound Medical to Host Investor Event at AUA 2025\n\n\n\n TORONTO, March 25, 2025 (GLOBE NEWSWIRE) --\n \n Profound Medical Corp.\n \n (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will host a hybrid (in-person and virtual) investor event on Monday, April 28, 2025, during the American Urological Association’s (“AUA”) Annual Meeting in Las Vegas, NV, from 3:30 p.m. to 5:00 p.m. Pacific Time (6:30 p.m. to 8:00 p.m. Eastern Time).\n \n\n “The program will feature presentations from members of Profound’s management team as well as by leading physicians on: (1) TULSA-PRO\n \n ®\n \n and its unrivalled flexibility to treat a wide variety of prostate disease patients; (2) peri-operative results from the Level 1 CAPTAIN post-market study comparing the TULSA procedure to radical prostatectomy in men with localized prostate cancer; (3) the upcoming TULSA-AI\n \n ®\n \n module for BPH, including a live demonstration of the technology; and (4), the progress we are making with our TULSA+ program, which combines the TULSA-PRO\n \n ®\n \n system and consumables with Siemens Healthineers’ interventional MRI, Magnetom Free.Max, as a total prostate solution,” commented Arun Menawat, Profound’s CEO and Chairman.\n \n\n\n About Profound Medical Corp.\n \n\n\n Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.\n \n\n Profound is commercializing TULSA-PRO\n \n ®\n \n , a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO\n \n ®\n \n system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs rea...